Severe adverse effects associated with tyrosine kinase inhibitors therapy in chronic myeloid leukaemia – case reports and literature review

  • Frosina Krstanovska
  • Irena Umek Bricman
  • Nataša Fikfak
  • Marija Čeh
  • Irena Preložnik Zupan

Abstract

Background: Chronic myeloid leukaemia is a clonal myeloproliferative disorder of myeloid progenitor cells. The availability of moleculartargeted therapy with tyrosine kinase inhibitors has changed the course and treatment for patients with chronic myeloid leukemia. The long-term follow-up of adverse events amongst the kinase inhibitors played role in forming decision-making algorithms for the use of this highly effective group of therapeutics. Patients and methods: In this paper, four CML patients are presented, treated with different tyrosine kinase inhibitors. Haematologic toxicity of kinase inhibitors is the most frequent adverse effect; however, non-haematological adverse effects should also not be neglected. Conclusions: Tyrosine kinase inhibitors have changed the therapy of CML, the treatment of these patients is a long-term process. Therefore, to know adverse effects is the matter of great importance in order to promptly recognise them and treat them properly.

Downloads

Download data is not yet available.
Published
2011-05-01
How to Cite
1.
Krstanovska F, Umek Bricman I, Fikfak N, Čeh M, Preložnik Zupan I. Severe adverse effects associated with tyrosine kinase inhibitors therapy in chronic myeloid leukaemia – case reports and literature review. ZdravVestn [Internet]. 1May2011 [cited 7Apr.2020];80(5). Available from: https://vestnik.szd.si/index.php/ZdravVest/article/view/170
Section
Case report, short scientific article

Most read articles by the same author(s)

1 2 > >>